Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Multicentric Study: Efficacy Evaluation of Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy on Disease-free-survival (DFS) in Patients With Resectable Head and Neck Mucosal Melanoma
Brief Summary: The main objective will be to estimate the disease free survival (DFS) of patients with resectable head and neck mucosal melanomas treated by neo-adjuvant anti-PD1 (in combination or not with lenvatinib) followed by surgery, radiotherapy and maintenance immunotherapy in order to compare it to historical DFS results of this kind of patients treated by surgery and radiotherapy. Our primary end-point will be disease-free survival at 2 years


Options:
A: Arm Label: Cohort A; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab, Procedure: Surgery, Radiation: IMRT | Arm Label: Cohort B; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab, Procedure: Surgery, Radiation: IMRT, Drug: Lenvatinib | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Cohort A, Cohort B | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Cohort A, Cohort B | Intervention Type: RADIATION; Name: IMRT; Assigned to Arm(s): Cohort A, Cohort B | Intervention Type: DRUG; Name: Lenvatinib; Assigned to Arm(s): Cohort B
B: Arm Label: Dostarlimab (TSR-042) (singly); Type: EXPERIMENTAL; Interventions: Drug: Dostarlimab (TSR-042) (singly) | Arm Label: Dostarlimab (TSR-042) and Cobolimab TSR-022 (combination); Type: EXPERIMENTAL; Interventions: Drug: Dostarlimab (TSR-042) and TSR-022 (combination) | Intervention Type: DRUG; Name: Dostarlimab (TSR-042) (singly); Assigned to Arm(s): Dostarlimab (TSR-042) (singly) | Intervention Type: DRUG; Name: Dostarlimab (TSR-042) and TSR-022 (combination); Assigned to Arm(s): Dostarlimab (TSR-042) and Cobolimab TSR-022 (combination)
C: Arm Label: Neoadjuvant treatment + Adjuvant treatment; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Adjuvant treatment; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Neo treat with patho response-driven Adju treat or observation; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Adjuvant treatment, Neo treat with patho response-driven Adju treat or observation, Neoadjuvant treatment + Adjuvant treatment | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Neo treat with patho response-driven Adju treat or observation, Neoadjuvant treatment + Adjuvant treatment
D: Arm Label: Treatment (dabrafenib, trametinib, surgery); Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Other: Laboratory Biomarker Analysis, Procedure: Therapeutic Conventional Surgery, Drug: Trametinib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery)

Answer: A